CRMD CorMedix Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * Duncan Gregory Scott	2. Issuer Name and Ticker or Trading Symbol CorMedix Inc. [ CRMD ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner _____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle) 400 CONNELL DRIVE, SUITE 5000	3. Date of Earliest Transaction (MM/DD/YYYY) 11/2/2020
(Street) BERKELEY HEIGHTS, NJ 07922 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Common Stock)	$5.0000	11/2/2020		A		20000.0000		(1)	11/2/2030	Common Stock	20000.0000	$0.0000	20000.0000	D
Stock Option (Right to Buy Common Stock)	$5.0000	11/2/2020		A		2500.0000		(2)	11/2/2030	Common Stock	2500.0000	$0.0000	2500.0000	D

Explanation of Responses:
(1)	These options were granted on 11/02/2020. One-third of the options vested on the date of grant. One-third of the options will vest on each of the first and second anniversaries of the date of grant, subject to continued service on the board.
(2)	These options were granted on 11/02/2020 and are subject to monthly vesting in equal installments during the one-year period beginning on December 2, 2020, subject to continued service on the board.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Duncan Gregory Scott 400 CONNELL DRIVE, SUITE 5000 BERKELEY HEIGHTS, NJ 07922	X

Signatures
/s/ Greg Duncan		11/4/2020
**Signature of Reporting Person		Date